Literature DB >> 27161642

Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226.

Ronald N Jones1, Kelley A Fedler2, Nicole E Scangarella-Oman3, James E Ross2, Robert K Flamm2.   

Abstract

Gepotidacin, a novel triazaacenaphthylene antibacterial agent, is the first in a new class of type IIA topoisomerase inhibitors with activity against many biothreat and conventional pathogens, including Neisseria gonorrhoeae To assist ongoing clinical studies of gepotidacin to treat gonorrhea, a multilaboratory quality assurance investigation determined the reference organism (N. gonorrhoeae ATCC 49226) quality control MIC range to be 0.25 to 1 μg/ml (88.8% of gepotidacin MIC results at the 0.5 μg/ml mode).
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27161642      PMCID： PMC4914643          DOI： 10.1128/AAC.00527-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Type IIA topoisomerase inhibition by a new class of antibacterial agents.

Authors:  Benjamin D Bax; Pan F Chan; Drake S Eggleston; Andrew Fosberry; Daniel R Gentry; Fabrice Gorrec; Ilaria Giordano; Michael M Hann; Alan Hennessy; Martin Hibbs; Jianzhong Huang; Emma Jones; Jo Jones; Kristin Koretke Brown; Ceri J Lewis; Earl W May; Martin R Saunders; Onkar Singh; Claus E Spitzfaden; Carol Shen; Anthony Shillings; Andrew J Theobald; Alexandre Wohlkonig; Neil D Pearson; Michael N Gwynn
Journal:  Nature       Date:  2010-08-04       Impact factor: 49.962

2.  Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains.

Authors:  Douglas J Biedenbach; Lisa L Turner; Ronald N Jones; David J Farrell
Journal:  Diagn Microbiol Infect Dis       Date:  2012-07-21       Impact factor: 2.803

3.  First nationwide study regarding ceftriaxone resistance and molecular epidemiology of Neisseria gonorrhoeae in China.

Authors:  Shao-Chun Chen; Yue-Ping Yin; Xiu-Qin Dai; Magnus Unemo; Xiang-Sheng Chen
Journal:  J Antimicrob Chemother       Date:  2015-10-15       Impact factor: 5.790

4.  Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone.

Authors:  Makoto Ohnishi; Daniel Golparian; Ken Shimuta; Takeshi Saika; Shinji Hoshina; Kazuhiro Iwasaku; Shu-ichi Nakayama; Jo Kitawaki; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

5.  Analysis of Neisseria gonorrhoeae azithromycin susceptibility in the United States by the Gonococcal Isolate Surveillance Project, 2005 to 2013.

Authors:  Robert D Kirkcaldy; Olusegun Soge; John R Papp; Edward W Hook; Carlos del Rio; Grace Kubin; Hillard S Weinstock
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

6.  High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.

Authors:  Magnus Unemo; Johan Ringlander; Catherine Wiggins; Hans Fredlund; Susanne Jacobsson; Michelle Cole
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

7.  Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model.

Authors:  Wonhee So; Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

8.  In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates.

Authors:  Christoph Hauser; Lea Hirzberger; Magnus Unemo; Hansjakob Furrer; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2014-12-29       Impact factor: 5.191

9.  A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea.

Authors:  Edward W Hook; Matthew Golden; Brian D Jamieson; Paula B Dixon; Hanne S Harbison; Sylvan Lowens; Prabhavathi Fernandes
Journal:  Clin Infect Dis       Date:  2015-06-18       Impact factor: 9.079

10.  In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae.

Authors:  Lindley A Barbee; Olusegun O Soge; King K Holmes; Matthew R Golden
Journal:  J Antimicrob Chemother       Date:  2014-01-26       Impact factor: 5.790
View more
  5 in total

1.  In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae.

Authors:  D J Farrell; H S Sader; P R Rhomberg; N E Scangarella-Oman; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

Review 2.  Topoisomerases as anticancer targets.

Authors:  Justine L Delgado; Chao-Ming Hsieh; Nei-Li Chan; Hiroshi Hiasa
Journal:  Biochem J       Date:  2018-01-23       Impact factor: 3.857

3.  Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria.

Authors:  R K Flamm; D J Farrell; P R Rhomberg; N E Scangarella-Oman; H S Sader
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

4.  In Vitro and In Vivo Activities of TP0480066, a Novel Topoisomerase Inhibitor, against Neisseria gonorrhoeae.

Authors:  Aiko Masuko; Iichiro Takata; Kiyoko Fujita; Hirotoshi Okumura; Fumihito Ushiyama; Hideaki Amada; Hiroyuki Sugiyama
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

5.  A Novel Oral GyrB/ParE Dual Binding Inhibitor Effective against Multidrug-Resistant Neisseria gonorrhoeae and Other High-Threat Pathogens.

Authors:  Steven Park; Riccardo Russo; Landon Westfall; Riju Shrestha; Matthew Zimmerman; Veronique Dartois; Natalia Kurepina; Barry Kreiswirth; Eric Singleton; Shao-Gang Li; Nisha Mittal; Yong-Mo Ahn; Joseph Bilotta; Kristie L Connolly; Ann E Jerse; Joel S Freundlich; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2022-08-16       Impact factor: 5.938
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.